Physician profile
Hilary Gomolin
NPI 1104874916
$6,679.07
in general payments reported to CMS, 2019-2025
45 companies · $919 in 2025
The $919 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,149 · 2020: $181 · 2021: $456 · 2022: $731 · 2023: $965 · 2024: $1,277 · 2025: $919.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,141 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,140.98 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $601.89 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $418.07 | 2019-2025 | Reblozyl, Opdivo, Opdualag |
| Celgene Corporation | $379.29 | 2019-2024 | Reblozyl, Pomalyst, Opdualag |
| Genzyme Corporation | $361.25 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $350.44 | 2019-2025 | |
| Genentech USA, INC. | $347.54 | 2019-2025 | Itovebi, Tecentriq, Phesgo |
| Janssen Biotech, INC. | $314.82 | 2019-2025 | Rybrevant |
| Alexion Pharmaceuticals, INC. | $303.09 | 2019-2025 | Ultomiris |
| Incyte Corporation | $302.22 | 2019-2025 | Jakafi |
| Merck Sharp & Dohme LLC | $294.49 | 2019-2024 | Keytruda |
| Kite Pharma, INC. | $246.31 | 2021-2024 | Yescarta |
| Abbvie INC. | $239.51 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $224.93 | 2019-2024 | Alunbrig, Iclusig, Fruzaqla |
| Lilly USA, LLC | $180.72 | 2019-2025 | Verzenio, Jaypirca |
| Astrazeneca Pharmaceuticals Lp | $164.89 | 2019-2025 | Tagrisso |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $163.57 | 2022-2024 | |
| Astellas Pharma US INC | $139.82 | 2019-2024 | Xospata |
| Eisai INC. | $139.22 | 2019-2024 | |
| Daiichi Sankyo INC. | $138.87 | 2019-2025 | Enhertu, Datroway |
| Pharmacyclics LLC, An Abbvie Company | $133.76 | 2019-2023 | Epkinly |
| Exelixis INC. | $105.65 | 2019-2025 | Cabometyx |
| Mirati Therapeutics, INC. | $99.54 | 2023-2024 | Krazati |
| Array Biopharma INC | $91.39 | 2024-2025 | Braftovi, Mektovi, Lorbrena |
| Amgen INC. | $88.86 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.61 | 2019-2025 | |
| Seagen INC. | $75.02 | 2019-2023 | Tukysa |
| Glaxosmithkline, LLC. | $66.05 | 2024 | Jemperli, Zejula, Ojjaara |
| Regeneron Healthcare Solutions, INC. | $63.75 | 2024-2025 | Libtayo |
| Ipsen Biopharmaceuticals, INC | $63.47 | 2019-2023 | Somatuline Depot, Onivyde |
| Bayer Healthcare Pharmaceuticals INC. | $57.54 | 2019-2024 | |
| Caris Mpi, INC. | $55.34 | 2025 | Mi Cancer Seek |
| Aveo Pharmaceuticals, INC. | $48.38 | 2023-2025 | Fotivda |
| Adaptive Biotechnologies Corporation | $47.66 | 2023-2024 | Clonoseq |
| Beigene USA, INC. | $41.20 | 2022-2025 | Brukinsa |
| Aurobindo Pharma USA, INC. | $40.72 | 2019-2020 | |
| Agios Pharmaceuticals, INC. | $36.09 | 2019-2020 | |
| Dova Pharmaceuticals | $25.18 | 2021 | |
| Amag Pharmaceuticals, INC. | $24.86 | 2019 | |
| Taiho Oncology, INC. | $20.69 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $19.51 | 2023 | Sancuso |
| Beone Medicines USA, INC. | $19.50 | 2025 | Brukinsa |
| Sun Pharmaceutical Industries INC. | $17.82 | 2019 | |
| Tesaro, INC. | $17.70 | 2019 | |
| Kyowa Kirin, INC. | $15.92 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hilary Gomolin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.